Please provide your email address to receive an email when new articles are posted on . Renin-angiotensin-aldosterone system inhibitor use in patients with hypertension and intracranial aneurysm was ...

Treatments that target the renin-angiotensin-aldosterone system (RAAS) don’t improve outcomes in adult patients hospitalized with acute COVID-19. Three separate trials of different RAAS-related ...

A recent study posted to the medRxiv* preprint server investigated the association of renin-angiotensin-aldosterone system (RAAS)-mediated hypertension (HT) with coronavirus disease 2019 (COVID-19).

RAAS inhibitors in MASLD are linked to reduced liver cancer risk in a Taiwan study. Learn more about the findings and clinical implications.

In a recent study posted to the medRxiv* preprint server, researchers conducted an umbrella review and meta-analysis of the renin-angiotensin-aldosterone system (RAAS) inhibitors' impact on ...

Discontinuation of RAAS inhibitors is often the first approach to manage hyperkalemia. Discontinuation of renin–angiotensin-aldosterone system (RAAS) inhibitors after the first hyperkalemia episode ...

Please provide your email address to receive an email when new articles are posted on . Many international medical societies have endorsed the continuation of renin-angiotensin-aldosterone system ...